Anagenics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	2.8yrs

Recent management updates

Recent updates

How Much is Cellmid's (ASX:CDY) CEO Getting Paid?

Dec 17

CEO

Anagenics has no CEO, or we have no data on them.

Board Members

Name	Position	Tenure	Compensation	Ownership
Scott Greasley	Executive Director	2.3yrs	AU$380.94k	0.52% A$ 19.1k
Alexander Beard	Non-Executive Chairman	2.8yrs	AU$40.00k	0.94% A$ 34.7k
Phillip Christopher	Non-Executive Director	3yrs	AU$51.25k	0.41% A$ 15.0k

2.8yrs

Average Tenure

Experienced Board: AN1's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Anagenics Management

Management criteria checks 0/4

Key information

Recent management updates

Anagenics Limited, Annual General Meeting, Nov 26, 2024

Anagenics Limited Announces Retirement of Karen Mathews as Chief Executive Officer

Anagenics Limited, Annual General Meeting, Nov 27, 2023

Anagenics Limited Appoints Karen Matthews as Non-Executive Director

Anagenics Approves the Election of Mr. Alexander Beard as A Director

No independent directors

Recent updates

Anagenics Limited, Annual General Meeting, Nov 26, 2024

Matthew Perry, Sarah Jane Perry, and entities they control completed the acquisition of Face Medigroup Retail Pty Ltd from Anagenics Limited (ASX:AN1).

Anagenics Limited Announces Retirement of Karen Mathews as Chief Executive Officer

Matthew Perry, Sarah Jane Perry, and entities they control agreed to acquire Face Medigroup Retail Pty Ltd from Anagenics Limited (ASX:AN1).

New major risk - Financial position

Anagenics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.32068 million.

Anagenics Limited, Annual General Meeting, Nov 27, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.017 loss in FY 2022)

Anagenics Limited (ASX:AN1) agreed to acquire Face MediGroup for AUD 1.3 million.

New minor risk - Financial data availability

Anagenics Limited Appoints Karen Matthews as Non-Executive Director

First half 2023 earnings released: AU$0.002 loss per share (vs AU$0.009 loss in 1H 2022)

Anagenics Limited (ASX:AN1) acquired Uspa Global Pty. Ltd. from BWX Limited (ASX:BWX).

Anagenics Approves the Election of Mr. Alexander Beard as A Director

No independent directors

Anagenics Limited, Annual General Meeting, Nov 29, 2022

Anagenics Limited Announces Resignation of Dennis Eck as Director

Full year 2022 earnings released: AU$0.017 loss per share (vs AU$0.027 loss in FY 2021)

Anagenics Limited Appoints Scott Mitchell Greasley as Director

Anagenics Limited Appoints Matthew Dudek as Acting Chief Executive Officer, Effective 28 February 2022

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Anagenics Limited Appoints Mr. Alexander (Sandy) Beard as Director

Full year 2021 earnings released: AU$0.027 loss per share (vs AU$0.045 loss in FY 2020)

Full year 2021 earnings released: AU$0.027 loss per share (vs AU$0.05 loss in FY 2020)

An unknown buyer signed a binding agreement to acquired Lyramid Limited from Cellmid Limited (ASX:CDY) for AUD 0.5 million

First half 2021 earnings released: AU$0.019 loss per share (vs AU$0.016 loss in 1H 2020)

Cellmid Limited Publishes Data on Novel Proprietary FGF5 Aptamer

Cellmid Limited Receives the First Order from Ourui Health Management Limited

Cellmid Limited Announces Executive Changes

How Much is Cellmid's (ASX:CDY) CEO Getting Paid?

Cellmid Limited, Advangen Limited and Advangen Inc. Signs 10 Year Chinese Distribution Agreement with Ourui Health Management Limited

Cellmid Limited Appoints Sarah Eck-Thompson as Director

Full year earnings released - AU$0.05 loss per share

CEO

Board Members

Average Tenure